Status:
COMPLETED
Clinical Study on the Efficacy and Safety of Qingre Heji in the Treatment of Acute Upper Respiratory Tract Infection
Lead Sponsor:
Shengjing Hospital
Conditions:
Acute Upper Respiratory Tract Infection
Traditional Chinese Medicine
Eligibility:
All Genders
18-85 years
Phase:
PHASE1
PHASE2
Brief Summary
Originating from China, TCM complements conventional approaches by alleviating symptoms, balancing physical conditions, and enhancing immunity. Clinical studies have shown TCM to be safe and effective...
Eligibility Criteria
Inclusion
- 1: Voluntarily sign informed consent
- 2: Age ≥ 18 years old
- 3: Meet the diagnostic criteria of acute respiratory tract infection: Internal Medicine edited by chenhaozhu (9th Edition, people's Health Publishing House)
Exclusion
- 1: Legal infectious diseases with upper respiratory symptoms
- 2: Patients with severe pneumonia
- 3: Severe primary diseases such as cardiovascular, cerebrovascular, liver, kidney and hematopoietic system
- 4: After this episode, he has received other antiviral, anti-inflammatory, antipyretic and analgesic drugs or any other drugs to treat colds
- 5: Pregnant or lactating women
- 6: Allergic constitution and drug allergy
- 7: Psychopath
- 8: Those who have participated in other clinical trials within three months
- 9: Persons with a history of drug abuse
- 10: Other circumstances that the investigator believes are not suitable for enrollment
Key Trial Info
Start Date :
February 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2024
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT06520618
Start Date
February 1 2023
End Date
February 1 2024
Last Update
July 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China, 110000